VIVA BIOTECH(01873),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01873 VIVA BIOTECH

Trading 04-28 10:25:19

1.730

+0.030

+1.76%

High1.770	Low1.700	Vol1.05M
Open1.700	D1 Closing1.700	Amplitude4.12%
Mkt Cap3.68B	Tradable Cap3.68B	Total Shares2.13B
T/O1.83M	T/O Rate0.05%	Tradable Shares2.13B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01873","market":"HK","secType":"STK","nameCN":"VIVA BIOTECH","latestPrice":1.73,"timestamp":1777342691928,"preClose":1.7,"halted":0,"volume":1052500,"delay":0,"changeRate":0.01764705882352943,"floatShares":2130000000,"shares":2130000000,"eps":0.10326093088857544,"marketStatus":"Trading","change":0.03,"latestTime":"04-28 10:25:19","open":1.7,"high":1.77,"low":1.7,"amount":1833760,"amplitude":0.041176,"askPrice":1.74,"askSize":102500,"bidPrice":1.73,"bidSize":29000,"shortable":3,"etf":0,"ttmEps":0.1307971791255289,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1777348800000},"marketStatusCode":2,"adr":0,"listingDate":1557331200000,"exchange":"SEHK","adjPreClose":1.7,"openAndCloseTimeList":[[1777339800000,1777348800000],[1777352400000,1777363200000]],"volumeRatio":1.395453,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01873/tweets","defaultTab":"tweets","newsList":[{"id":"1112185487","title":"VIVA BIOTECH's Shares Nearly Halved in Three Months, Lagging Behind CXO Sector's Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=1112185487","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112185487?lang=en_us&edition=fundamental","pubTime":"2026-04-27 17:15","pubTimestamp":1777281318,"startTime":"0","endTime":"0","summary":"Following a rebound to a阶段性 high of HK$2.86 in late January, VIVA BIOTECH's (01873) stock price has experienced a nearly three-month decline. It was observed that on April 27, the stock hit an...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","BK1576","CXO","01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175975437","title":"VIVA BIOTECH 2025 ESG Report: Net Profit Up 21.30%, Carbon Emissions Cut 6%, AI-Driven Drug Discovery Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=1175975437","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175975437?lang=en_us&edition=fundamental","pubTime":"2026-04-22 18:23","pubTimestamp":1776853404,"startTime":"0","endTime":"0","summary":"VIVA BIOTECH released its seventh ESG report, detailing 2025 operating and sustainability results. Financial Performance   • Revenue grew 21.31% year-on-year to RMB 1.73 billion.   • Net profit...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101767873","title":"维亚生物2025年净利同比增至人民币2.693亿元，CRO与CDMO业务双线发力","url":"https://stock-news.laohu8.com/highlight/detail?id=1101767873","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101767873?lang=en_us&edition=fundamental","pubTime":"2026-04-22 17:11","pubTimestamp":1776849081,"startTime":"0","endTime":"0","summary":"维亚生物在其截至2025年12月31日止年度的业绩报告中显示，期内收入为人民币17.294亿元（2024年：19.867亿元），同比下降12.9%。尽管营收下滑，全年净利润依然从上年的2.220亿元增长至2.693亿元，同比上升21.3%。同期毛利为6.556亿元，毛利率由34.6%提升至37.9%，反映出更有效的成本管控与业务组合优化。公司经调整后（非IFRS）净利润从3.146亿元增加至3.3...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维亚生物2025年净利同比增至人民币2.693亿元，CRO与CDMO业务双线发力","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148827036","title":"Viva Biotech calls 26 June 2026 AGM; proposes 20 % share-issue mandate, 10 % buy-back limit and re-election of three directors","url":"https://stock-news.laohu8.com/highlight/detail?id=1148827036","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148827036?lang=en_us&edition=fundamental","pubTime":"2026-04-22 17:05","pubTimestamp":1776848709,"startTime":"0","endTime":"0","summary":"Viva Biotech Holdings will hold its annual general meeting on 26 June 2026 at 10:00 a.m. (Meeting Room A615, 735 Ziping Road, Zhoupu Town, Pudong New District, Shanghai). Key resolutions to be put to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629101541","title":"VIVA Biotech Holdings announces annual general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629101541","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629101541?lang=en_us&edition=fundamental","pubTime":"2026-04-22 16:39","pubTimestamp":1776847142,"startTime":"0","endTime":"0","summary":"Viva Biotech Holdings will hold annual general meeting in Shanghai on June 26, 2026.Shareholders will receive audited consolidated financial statements for year ended Dec. 31, 2025.Meeting will vote on re-election of Ren Delin, Wu Yuting, Fu Lei.Board will seek mandate to set directors’ remuneration, reappoint Ernst & Young as auditor, set auditor fees.Resolutions include general mandates to issue shares up to 20% of issued share capital, repurchase shares up to 10%, extend issuance mandate by shares repurchased.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL4F6w14:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01873","BK1576","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629149015","title":"Viva Biotech publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2629149015","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629149015?lang=en_us&edition=fundamental","pubTime":"2026-04-22 16:36","pubTimestamp":1776846966,"startTime":"0","endTime":"0","summary":"Viva Biotech issued its 2025 annual report, highlighting a return to growth in CRO activity supported by improving biopharma funding conditions and stronger China drug deal flow.AI-driven drug discovery expanded across operations, with AI-enabled work contributing about 12% of CRO revenue and covering 196 projects for 73 customers.CDMO unit Langhua Pharmaceutical improved profitability through product mix changes, with 2 commercial-stage programs expected to launch in 2026 and 2027.Investment and incubation business monetized several exits, generating RMB 150.5 million investment income in 2025.Board did not recommend a final dividend for year ended Dec. 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings pub","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL41z8Sq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","01873","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629198082","title":"Viva Biotech hosts webinar on AI and flow chemistry in drug synthesis scale-up","url":"https://stock-news.laohu8.com/highlight/detail?id=2629198082","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629198082?lang=en_us&edition=fundamental","pubTime":"2026-04-21 17:58","pubTimestamp":1776765513,"startTime":"0","endTime":"0","summary":"Viva Biotech hosted its “AI x Flow Chemistry: From Bench to Business - Academic and Industry Perspectives” webinar on April 21, 2026.Viva positioned flow chemistry as a scalable, integrated capability across discovery and manufacturing, citing internal case studies that delivered more than 20 g/day of a photochemical scaffold, 80 g/day of crude difluoromethyl intermediate, and 1,000 kg via a continuous-flow Curtius rearrangement within two months.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL3zWvrt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","01873","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197440022","title":"Viva Biotech Files March 2026 Monthly Return: Share Capital Stable, 15.92 Million Options Outstanding","url":"https://stock-news.laohu8.com/highlight/detail?id=1197440022","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197440022?lang=en_us&edition=fundamental","pubTime":"2026-04-09 15:40","pubTimestamp":1775720441,"startTime":"0","endTime":"0","summary":"Viva Biotech Holdings submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited for the period ended 31 March 2026. Key takeaways are as follows: 1. Authorised Share...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111816651","title":"Viva Biotech Reports Stable Share Capital Structure for January 2026; 4.42 Million Post-IPO Options Lapse","url":"https://stock-news.laohu8.com/highlight/detail?id=1111816651","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111816651?lang=en_us&edition=fundamental","pubTime":"2026-04-09 15:20","pubTimestamp":1775719239,"startTime":"0","endTime":"0","summary":"Viva Biotech Holdings disclosed its Monthly Return for Equity Issuers for the period ended 31 January 2026, confirming a steady capital structure and compliance with Hong Kong Stock Exchange...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625987380","title":"Asian Penny Stocks To Consider In April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625987380","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625987380?lang=en_us&edition=fundamental","pubTime":"2026-04-07 12:05","pubTimestamp":1775534708,"startTime":"0","endTime":"0","summary":"Amidst ongoing geopolitical tensions and energy market volatility, Asian markets are navigating a complex landscape with mixed signals from global indices. Penny stocks, though often overlooked, remain an intriguing area of investment for those seeking potential growth in smaller or newer companies. By focusing on firms with strong financial health, investors can uncover opportunities that might offer both stability and potential upside; here we explore three such promising candidates within...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice1-main-header/1585186668959","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice1-main-header/1585186668959"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/software/hkg-9959/linklogis-shares/news/asian-penny-stocks-to-consider-in-april-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/software/hkg-9959/linklogis-shares/news/asian-penny-stocks-to-consider-in-april-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1242518931.SGD","SGXZ27511609.SGD","BK1589","LU0082770016.USD","SG9999000475.SGD","SG9999014484.SGD","BK8040","SG9999014492.USD","BK6504","LU0516422440.USD","LU0516422952.EUR","SG9999002679.SGD","BK6065","SGXZ24219693.SGD","SG9999013486.USD","LU0620787316.HKD","LU0164939612.USD","BK1554","00968","LU0516423174.USD","BK6081","SGXZ43160589.SGD","LU0516422366.SGD","LU0082770016.SGD","SG9999000343.SGD","BK1169","SG9999003826.SGD","SGXZ58947870.SGD","LU1983299162.USD","IE00BZ08YT58.USD","SG9999013478.USD","09959","IE00BZ08YR35.GBP","SG9999004360.SGD","BK4139","SG9999013460.SGD","01873","IE00BZ08YS42.EUR","LU1242518857.USD","SG9999016042.SGD","LU0516423091.SGD","LU0979878070.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624548014","title":"Viva Biotech Holdings (SEHK:1873) One Off Gain Clouds Trailing 12.7% Margin Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2624548014","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624548014?lang=en_us&edition=fundamental","pubTime":"2026-04-01 22:31","pubTimestamp":1775053866,"startTime":"0","endTime":"0","summary":"Viva Biotech Holdings (SEHK:1873) has reported FY 2025 first half revenue of CN¥831.9 million and basic EPS of CN¥0.058, against a backdrop of trailing twelve month revenue of CN¥1.7 billion and EPS of CN¥0.10 that has been associated with earnings growth of 31.4% over the past year and a 16.9% annualised pace over five years. Over the last twelve months, net profit margin has been reported at 12.7% versus 8.4% in the prior year period, so the latest print comes with visibly thicker margins...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1873/viva-biotech-holdings-shares/news/viva-biotech-holdings-sehk1873-one-off-gain-clouds-trailing","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1873/viva-biotech-holdings-shares/news/viva-biotech-holdings-sehk1873-one-off-gain-clouds-trailing","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4121","BK4585","XBI","VBIZF","01873","BK4581","BK1576","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179153130","title":"Stock Track | Viva Biotech Plummets 7.04% Intraday on Mixed 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1179153130","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179153130?lang=en_us&edition=fundamental","pubTime":"2026-03-31 16:00","pubTimestamp":1774944013,"startTime":"0","endTime":"0","summary":"Viva Biotech's stock plummeted 7.04% during intraday trading on Tuesday, following the release of its 2025 financial results.The company reported a rise in attributable profit to 219.8 million yuan...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623341287","title":"Press Release: Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2623341287","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623341287?lang=en_us&edition=fundamental","pubTime":"2026-03-30 23:02","pubTimestamp":1774882920,"startTime":"0","endTime":"0","summary":"Gross profit margin recorded 37.9%, a YOY increase of 3.3 pp. Net profit recorded RMB269.3 million, a YOY increase 21.3%. Adjusted non-IFRS net profit recorded RMB335.3 million, a YOY increase of nearly 6.6%. CRO Business Sustained Recovery in Growth, AI-Enabled Drug Discovery Technology Maintained Industry-Leading Advantages. Throughout 2025, revenue from the Company's CRO business rose from RMB810.9 million in the same period last year to RMB848.6 million, representing a growth of approximately 4.7%. Corresponding adjusted gross profit increased from RMB357.1 million in the same period last year to RMB383.1 million, an increase of approximately 7.3%. The total number of CRO clients of the Company increased to 1,866, including the World's top Ten pharmaceutical companies, revenue from the top ten clients accounted for 25.7% of our total revenue.The Company has continuously strengthened the deployment of new platforms and raised the technical barriers of core platforms, and","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIPO","BK4588","CDMO","XBI","BK4139","01873","BK4581","BK4585","BK1576","AGIX","BK1141","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166647001","title":"Viva Biotech 2025 Results: Net Profit Jumps 21.30%, Margin Expansion Offsets Revenue Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1166647001","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166647001?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:25","pubTimestamp":1774869943,"startTime":"0","endTime":"0","summary":"Viva Biotech reported 2025 revenue of RMB 1.73 billion, down 12.90% year on year, as weaker CDMO sales offset steady CRO growth. However, gross profit margin widened to 37.90% from 34.60%, lifting...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168079100","title":"VIVA BIOTECH Announces Annual Profit Increase of 21.31% to 269 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1168079100","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168079100?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:18","pubTimestamp":1774869518,"startTime":"0","endTime":"0","summary":"VIVA BIOTECH (01873) has disclosed its financial results for the year ended December 31, 2025. The group reported annual revenue of 1.729 billion yuan, representing a decrease of 12.9% compared to...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","01873","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623311297","title":"VIVA Biotech FY25 net profit rises 21.3% to RMB 269 million; revenue drops 12.9% to RMB 1.7 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2623311297","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623311297?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:09","pubTimestamp":1774868975,"startTime":"0","endTime":"0","summary":"VIVA Biotech posted 2025 net profit of RMB 269 million, up 21.3%.Gross margin widened 3.3 percentage points to 37.9%.Adjusted non-IFRS net profit increased 6.6% to RMB 335 million, aided by CRO revenue growth, improved profitability from Langhua Pharmaceutical’s business mix optimization, and investment income from successful incubation exits.CRO revenue rose 4.7% to RMB 849 million, while management expects overall CRO growth in 2026 to remain at the current level on a healthy order backlog and expansion of AI-enabled platforms.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exch","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL4mq0Kg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","01873","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623311909","title":"VIVA Biotech Holdings FY Revenue RMB 1,729.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623311909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623311909?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:05","pubTimestamp":1774868732,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nPLX21DC0C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1141","01873","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107739607","title":"Viva Biotech (01873) Schedules 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Final Dividend Proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=1107739607","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107739607?lang=en_us&edition=fundamental","pubTime":"2026-03-18 16:40","pubTimestamp":1773823256,"startTime":"0","endTime":"0","summary":"Viva Biotech Holdings (Stock Code: 01873) has announced that its board of directors will convene on 30 March 2026. The meeting will focus on three core agenda items: 1. Reviewing and approving the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620235552","title":"VIVA Biotech Holdings schedules board meeting to approve annual results and consider final dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2620235552","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620235552?lang=en_us&edition=fundamental","pubTime":"2026-03-18 16:31","pubTimestamp":1773822718,"startTime":"0","endTime":"0","summary":"VIVA Biotech will hold a board meeting on March 30, 2026 to consider and approve its annual results for the year ended December 31, 2025. The board will also consider a recommendation on a final dividend at the same meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL7t7p77:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01873","BK1141","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620441524","title":"Viva Biotech collaborates with NVIDIA to advance AI-driven drug discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2620441524","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620441524?lang=en_us&edition=fundamental","pubTime":"2026-03-17 09:00","pubTimestamp":1773709228,"startTime":"0","endTime":"0","summary":"Viva Biotech is working with NVIDIA to optimize the Proteina-Complexa model for designing mini-binders targeting the ActRIIA receptor. The collaboration uses NVIDIA BioNeMo within Viva Biotech’s “Lab-in-the-Loop” workflow, combining computational design with protein production and biophysical evaluation. Viva Biotech said it is providing feedback from its AI-based sequence selection to improve the Proteina-Complexa model.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL3gQ9vX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4554","IE000ITXATA3.USD","IE000W1ABFV2.USD","LU1720051108.HKD","BK4141","LU0267386448.USD","BK4592","LU0289961442.SGD","LU0868494708.USD","LU1791710582.SGD","NVDS","BK4527","HK0000306685.HKD","LU1066053197.SGD","LU0211328371.USD","LU2413666426.HKD","01873","LU0308772762.SGD","LU2063271972.USD","LU1712237335.SGD","IE0004445239.USD","LU0642271901.SGD","SG9999014567.USD","SNVD.UK","SG9999014898.SGD","DIPS","LU0215105999.USD","LU2473716301.USD","SG9999000418.SGD","LU0786609619.USD","IE00BZ199S13.USD","LU2247934214.USD","LU2054465674.USD","LU0823414478.USD","IE00BQXX3C00.GBP","IE00BWXC8680.SGD","LU0348723411.USD","LU0109391861.USD","LU0106261372.USD","LU2023250504.SGD","LU1645745479.HKD","LU1153585028.USD","LU1778281490.HKD","LU0820561909.HKD","SG9999002224.SGD","LU1244550577.SGD","LU2420271590.USD","IE00BJLML261.HKD","LU0965509101.SGD","IE000YTNTUN2.SGD","NVDU","LU2471134879.HKD","IE00BHPRN162.USD","LU0557290698.USD","LU1699723380.USD","LU0080751232.USD","LU0006306889.USD","LU0466842654.USD","BK4567","SG9999002232.USD","LU1674673428.USD","LU2087625088.SGD","NVDX","LU2272731600.USD","LU0097036916.USD","NVDA","LU2756315318.SGD","LU2381873111.SGD","HK0000320264.USD","LU2750360641.GBP","LU0861579265.USD","LU0965509010.AUD","LU2286300806.USD","LU2746668974.SGD","LU0823434583.USD","IE00BJTD4N35.SGD","LU0390134368.USD","IE00BKPKM429.USD","IE0004445015.USD","LU2065170008.USD","LU0323591593.USD","LU1935042215.USD","IE0034235295.USD","LU0444971666.USD","LU2430703178.SGD","LU1917777945.USD","BK4543","LU1868836591.USD","LU2433249047.HKD","LU1861215975.USD","LU1127390331.HKD","BK1141","LU0256863902.USD","LU2111349929.HKD","LU2458330243.SGD","LU1623119135.USD","SGXZ31699556.SGD","LU0061475181.USD","LU2458330169.SGD","LU2087621335.USD","LU0979878070.USD","IE00BJJMRX11.SGD","LU0823421416.USD","LU0353189763.USD","LU0203202063.USD","LU2097344357.USD","LU2237957811.SGD","SG9999015341.SGD","LU0154236417.USD","LU0011850046.USD","LU1244550221.USD","LU0708994859.HKD","LU2191332357.HKD","BK4608","LU2506951792.HKD","LU1035775433.USD","LU1821325948.USD","LU0109392836.USD","LU1803068979.SGD","LU2592432038.USD","LU2236285917.USD","NVD","NVII","LU1935043023.USD","LU0053666078.USD","LU0234570918.USD","LU0957791311.USD","BK4548","LU1868836757.USD","IE00BQXX3F31.USD","LU2244417387.USD","LU2089284900.SGD","LU1119994496.HKD","IE00BYXW3230.USD","SG9999018857.SGD","LU0069063385.USD","BK4598","LU1815333072.USD","LU0310800379.SGD","LU1571399168.USD","SG9999004303.SGD","BK4585","LU0964807845.USD","LU2462157665.USD","LU2092627202.USD","LU1721428933.USD","LU2430703095.HKD","LU1435385759.SGD","LU2065171311.SGD","LU0345770308.USD","LU2168564495.EUR","LU1983260115.SGD","SG9999015986.USD","LU2213496289.HKD","HK0000914660.USD","LU2430703251.USD","LU2125909916.SGD","LU1496350171.SGD","LU1064131342.USD","BK4534","LU1935042488.USD","IE0034235188.USD","LU0354030511.USD","LU2237438978.USD","LU0788109477.HKD","LU2322448957.HKD","LU0640476718.USD","LU0943347566.SGD","GB00BDT5M118.USD","BK4533","IE00B19Z9505.USD","IE00B5949003.HKD","IE00B1BXHZ80.USD","LU0965509283.SGD","LU0417517546.SGD","LU2471134952.CNY","LU2461242641.AUD","LU2092937148.SGD","SG9999014914.USD","IE00B4JS1V06.HKD","LU0265550359.USD","LU1989772840.SGD","SG9999015978.USD","BK4588","IE00BQXX3D17.EUR","SG9999015358.SGD","IE00B775H168.HKD","LU2552382215.SGD","SG9999015952.SGD","LU1852331112.SGD","LU1989772923.USD","BK4587","LU1868836914.USD","LU0128525929.USD","LU0094547139.USD","IE00B775SV38.USD","LU2860962120.EUR","HK0000320223.HKD","LU2106854487.HKD","LU0187121727.USD","BK4579","IE0005OL40V9.USD","LU2211815571.USD","IE000KEQY171.SGD","IE00BKVL7J92.USD","LU0823434740.USD","3NVD.UK","SGXZ99366536.SGD","LU0274383776.USD","LU2168564222.USD","LU2543165471.USD","LU1989764748.USD","IE0001KFT4U8.USD","NVDS.UK","LU1145028129.USD","BK1576","LU1267930730.SGD","IE00B4YYXB79.USD","LU0353189680.USD","IE00B7KXQ091.USD","LU0689626769.HKD","LU1202635105.USD","LU0868494617.USD","IE00BFSS8Q28.SGD","LU1935042991.SGD","IE0004086264.USD","LU1923622614.USD","LU0683600562.USD","LU1548497426.USD","LU1496350502.SGD","LU0672654240.SGD","LU1244550494.USD","ANV","BK4581","LU2361044865.SGD","LU1951198990.SGD","LU1868837300.USD","LU2471134523.USD","LU0345769631.USD","LU2491050154.USD","LU0234572021.USD","LU2360032135.SGD","LU1791710400.SGD","IE0009G5SDU7.USD","IE00B3SWFQ91.USD","LU0210533765.USD","LU1366333091.USD","LU2271345857.HKD","LU2125154935.USD","LU2552382132.HKD","LU1316542783.SGD","LU1923622291.USD","BK4605","IE00BMPRXN33.USD","LU0276348264.USD","LU0158827948.USD","LU0079474960.USD","LU0528227936.USD","LU1868837136.USD","LU1400636574.HKD","LU2896262040.SGD","LU0225283273.USD","LU0823421333.USD","LU1069344957.HKD","LU1992135472.HKD","IE00B1XK9C88.USD","LU0472753341.HKD","LU0476273544.USD","LU0820562030.AUD","LU1914381329.SGD","LU1066051225.USD","IE00BK4W5M84.HKD","LU0061474960.USD","BK4612","IE00BK4W5L77.USD","LU1267930573.SGD","BK4550","LU2125909247.SGD","LU2249611893.SGD","SG9999015945.SGD","SG9999014575.USD","LU0708995401.HKD","LU0265550946.USD","LU2242650005.HKD","LU0787776722.HKD","LU1400636491.USD","LU1935043536.SGD","LU2108987350.USD","LU1633808545.USD","LU2089283258.USD","LU0175139822.USD","LU0198837287.USD","LU0289739343.SGD","LU1720051017.SGD","LU2250418816.HKD","LU1815336760.USD","LU2028103732.USD","SG9999018865.SGD","NVDG","LU0724617625.USD","LU0238689110.USD","LU0957808578.USD","LU2456880835.USD","LU2237957902.USD","LU0157215616.USD","LU0266013472.USD","LU1116320901.HKD","LU1232071149.USD","LU2746668461.USD","LU0124676726.USD","LU0170899867.USD","NVDB","LU1037948541.HKD","LU1718418525.SGD","IE00BJJMRY28.SGD","LU1551013425.SGD","LU1861220033.SGD","LU2125909593.SGD","LU2089985449.USD","SG9999001424.SGD","LU2361045086.USD","LU1267930490.SGD","LU0127658192.USD","LU1084165304.USD","IE0034235303.USD","LU1861127337.USD","LU1323610961.USD","LU0889565833.HKD","LU2265009873.SGD","LU0096364046.USD","LU2264538146.SGD","LU0107464264.USD","LU2083900584.USD","LU2322448791.USD","NVDD","LU0345768740.USD","LU0256863811.USD","LU1629891620.HKD","IE00BN29S564.USD","LU0210536198.USD","LU2487616109.SGD","LU1261432733.SGD","SG9999014906.USD","LU0316494557.USD","BK4503","IE00BD6J9T35.USD","LU2168563687.JPY","IE00B3M56506.USD","LU0203201768.USD","SGXZ51526630.SGD","LU2361044949.HKD","LU0077335932.USD","IE00BJTD4V19.USD","LU2505996681.GBP","SGXZ81514606.USD","IE00BKDWB100.SGD","LU1400636657.SGD","LU0211327993.USD","LU0820561818.USD","LU1934455863.HKD","LU2326559502.SGD","LU1066051498.USD","LU2065171402.SGD","LU1974910355.USD","LU2242649171.HKD","LU2097344431.USD","LU0354030438.USD","LU0081259029.USD","LU0494093205.USD","LU1280957306.USD","LU2294711713.HKD","BK4529","LU1814569148.SGD","LU0072462426.USD","LU2023250330.USD","NVDW","LU2931357623.SGD","NVD3.UK","LU2168564149.EUR","LU2505996509.AUD","LU0061474705.USD","LU2125909759.SGD","IE00BZ1G4Q59.USD","LU1642822529.SGD","LU2413666699.HKD","LU2357125470.USD","IE00BDCRKT87.USD","LU1923623000.USD","LU2750360997.AUD","LU0310799852.SGD","LU2077746001.SGD","LU0342679015.USD","LU1804176565.USD","LU1242518931.SGD","LU2023251221.USD","BK4551","IE00BMPRXQ63.HKD","BK4614","IE00B3S45H60.SGD","LU0070217475.USD","LU1839511570.USD","HK0000914686.HKD","LU2552382058.USD","LU1037948897.HKD","LU0345768153.USD","LU0096362180.USD","LU2360107168.USD","LU2463028550.USD","LU0210528500.USD","LU0345769128.USD","NVDQ","LU1934455277.USD","LU2290526834.HKD","NVIW.SI","IE00BDRTCR15.USD","SG9999014559.SGD","LU1670756490.USD","2NVD.UK","LU1691799644.USD","LU2403377893.USD","LU0158827781.USD","LU2491050071.SGD","SG9999014542.SGD","LU2452424414.USD","HK0000306701.USD","LU2272731782.SGD","LU0029864427.USD","LU2168564065.EUR","IE00BMPRXR70.SGD","LU1366192091.USD","LU1934455194.USD","LU2272731865.HKD","LU0882574139.USD","LU2417539215.USD","LU2756315664.SGD","LU0942090050.USD","LU0082616367.USD","LU2125154778.USD","LU1429558221.USD","NVD2.UK","LU0057025933.USD","LU1116320737.USD","LU0444973449.USD","LU1674673691.USD","LU0719512351.SGD","LU0345770993.USD","LU0985320562.USD","LU0048584097.USD","IE0003U64NQ7.SGD","NVDY","LU0056508442.USD","SGXZ23171101.USD","LU0289960550.SGD","LU1989764664.SGD","IE0009356076.USD","LU2360106780.USD","LU2491049909.HKD","LU1988902786.USD","LU0689472784.USD","LU2471134796.USD","SG9999017495.SGD","LU0511384066.AUD","LU2602419157.SGD","IE00B19Z8X17.USD","LU0347712357.USD","LU1066051811.HKD","LU0251132253.USD","IE00BFSS7M15.SGD","BK4532","LU2065169927.USD","LU1551013342.USD","LU1242518857.USD","LU2357305700.SGD","LU0320765059.SGD","LU1951200564.SGD","LU1992135399.USD","LU0965508806.USD","IE00B19Z8W00.USD","IE0004091025.USD","LU0823414551.USD","BK4549","SG9999014880.SGD"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.vivabiotech.com","stockEarnings":[{"period":"1week","weight":-0.0608},{"period":"1month","weight":-0.1866},{"period":"3month","weight":-0.32},{"period":"6month","weight":-0.2946},{"period":"1year","weight":0.1486},{"period":"ytd","weight":-0.0556}],"compareEarnings":[{"period":"1week","weight":-0.0165},{"period":"1month","weight":0.039},{"period":"3month","weight":-0.0443},{"period":"6month","weight":-0.016},{"period":"1year","weight":0.1795},{"period":"ytd","weight":0.0115}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"VIVA Biotech Holdings is an investment holding company. The Company has two segments. The Drug Discovery Services segment provides structure-based drug discovery services to biotech and pharmaceutical clients for preclinical innovative drug development. The Contract Design and Manufacturing (CDMO) and Commercialization Services segment is engaged in contract development and manufacturing services for small molecule Active Pharmaceutical Ingredients (APIs) and intermediates, as well as the trading of APIs, intermediates and finished products. The Company conducts business primarily in the United States, China, Europe and other regions.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.080145},{"month":2,"riseRate":0.285714,"avgChangeRate":0.018359},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.001599},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.029417},{"month":5,"riseRate":0.666667,"avgChangeRate":0.245742},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.034299},{"month":7,"riseRate":0.714286,"avgChangeRate":0.010126},{"month":8,"riseRate":0.428571,"avgChangeRate":0.041644},{"month":9,"riseRate":0.285714,"avgChangeRate":0.021762},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.044725},{"month":11,"riseRate":0.142857,"avgChangeRate":-0.040545},{"month":12,"riseRate":0.571429,"avgChangeRate":0.026236}],"exchange":"SEHK","name":"VIVA BIOTECH","nameEN":"VIVA BIOTECH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"VIVA BIOTECH(01873),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest VIVA BIOTECH(01873) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"VIVA BIOTECH,01873,VIVA BIOTECH股票,VIVA BIOTECH股票老虎,VIVA BIOTECH股票老虎国际,VIVA BIOTECH行情,VIVA BIOTECH股票行情,VIVA BIOTECH股价,VIVA BIOTECH股市,VIVA BIOTECH股票价格,VIVA BIOTECH股票交易,VIVA BIOTECH股票购买,VIVA BIOTECH股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"VIVA BIOTECH(01873),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest VIVA BIOTECH(01873) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}